PRASAD SUYASH 4
4 · Taysha Gene Therapies, Inc. · Filed Jul 7, 2022
Insider Transaction Report
Form 4
PRASAD SUYASH
CMO and Head of R&D
Transactions
- Sale
Common Stock
2022-07-05$3.51/sh−3,905$13,707→ 539,545 total - Sale
Common Stock
2022-07-06$3.79/sh−8,956$33,943→ 530,589 total
Footnotes (3)
- [F1]The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $4.00, inclusive.